Protagonist Therapeutics PTGX Cash Flow Statement (2015-2026)

NASDAQ PTGX
$134.86 -1.40 (-1.03%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Protagonist Therapeutics Quarterly Cash Flow Statement

Periods 46 quarters
Latest Sep 2026

Protagonist Therapeutics reported cash from operations of -$23.22M and free cash flow of -$23.46M for the quarter ended Sep 2026. This cash flow statement covers 46 quarters of results from Jun 2015 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-36.91M-20.93M-41.04M-31.23M-34.19M-33.73M-38.46M-34.11M27.34M207.34M-30.62M-33.21M131.67M-11.66M-34.77M-39.34M-44.38M3.78M162.85M220.02M
Depreciation and DepletionDep. & Depletion
0.24M0.25M0.26M0.27M0.25M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
0.24M0.25M0.26M0.27M0.26M0.25M0.24M0.24M0.25M0.24M0.24M0.23M0.12M0.24M0.30M0.36M0.38M0.41M0.40M0.41M
Share-based CompensationStock Comp.
5.02M5.94M6.81M5.95M5.51M7.58M8.34M6.77M6.60M9.35M8.94M10.17M9.09M13.80M10.91M10.56M10.70M14.52M14.04M14.36M
Deferred Taxes
Gains from Sales and DivestituresGains Divest
Gains from Investment SecuritiesGains Investment
-0.01M
Other non-cash itemsOther Non-Cash
0.58M0.58M0.58M0.58M0.58M0.58M0.58M0.58M0.58M0.58M0.65M0.42M0.42M0.57M0.57M0.11M0.35M0.44M0.44M0.45M
Change in Working Capital
Change in ReceivablesChange Receivables
-23.58M25.11M-0.08M0.12M-0.04M0.01M0.04M-10.00M-290.04M300.00M0.04M-165.00M165.00M-0.58M0.46M-53.54M40.25M-270.37M
Change in Account PayablesChange Payables
0.45M5.56M-6.38M3.94M-1.08M0.38M0.55M-3.20M-0.60M2.83M-0.20M-0.36M-1.43M1.24M0.38M2.42M-0.31M3.00M-4.90M2.46M
Change in Accrued ExpensesChange Accrued Exp.
4.70M-5.11M3.56M-6.57M-4.59M-8.38M2.72M5.40M-5.34M-2.87M-1.36M5.29M3.23M-11.82M3.44M7.55M5.41M-10.79M4.19M1.30M
Change in TaxesChange Taxes
-0.92M-0.03M3.33M-0.68M-1.60M1.64M-0.80M-1.89M
Change in Other Operating AssetsOther Assets Change
-0.48M22.31M-23.57M-0.59M-3.46M-0.75M-1.44M0.59M-0.16M0.92M2.01M1.16M-0.32M23.77M0.56M-22.34M0.37M1.92M-0.02M1.04M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.76M-0.83M-0.77M-0.67M-0.68M-0.69M-0.70M45.05M-5.39M-4.84M-4.25M-5.16M-5.25M-3.66M-6.96M-3.82M2.82M6.07M
Other Working Capital ChangesOther WC Changes
-0.28M-23.14M22.81M0.59M3.46M0.07M0.76M-1.28M-0.54M44.13M-7.40M-6.00M-3.93M-28.93M-5.80M18.68M-7.33M-5.73M2.84M5.02M
Other Operating Activities (as filed)
0.19M0.01M0.00M-0.01M0.00M0.00M0.00M
Cash from OperationsCash from Ops.
-26.94M-37.67M-13.64M-25.20M-31.64M-34.35M-26.24M-26.61M16.96M-27.43M268.62M-27.86M-29.18M125.36M-28.78M-1.94M-36.98M-48.94M219.05M-23.22M
Investing Activities
Capital ExpendituresCapex
0.20M0.27M0.29M0.16M0.07M0.01M0.18M0.40M0.02M0.24M0.03M0.78M0.31M0.55M0.81M0.09M0.14M0.22M0.17M0.24M
Change in Property, Plant and EquipmentChange in PP&E
-0.20M-0.27M-0.29M-0.16M-0.07M-0.01M-0.18M-0.40M-0.02M-0.24M-0.03M-0.78M-0.31M-0.55M-0.81M-0.09M-0.14M-0.22M-0.17M-0.24M
Purchase of InvestmentsInvestments Purchased
Sale and Maturity of InvestmentsInvestments Sold
58.75M51.63M81.31M89.60M84.60M37.90M32.00M45.80M36.70M71.98M86.87M58.73M105.99M120.18M122.78M102.65M153.23M160.09M132.41M102.62M
Cash from Investing ActivitiesCash from Investing
27.87M-4.48M34.73M57.28M3.94M9.83M25.76M-13.56M-61.29M6.07M-88.12M-208.71M-8.73M-94.40M54.81M-58.56M48.82M90.89M-2.43M93.43M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
14.55M24.30M
Net Long-Term Debt Issued (Repaid)Net LT Debt
14.55M24.30M
Net Debt Issuances and RepaymentsNet Debt Issuance
14.55M24.30M
Change in Capital Stock
Common Stock IssuedStock Issued
2.17M2.56M0.66M0.68M0.55M2.26M108.84M1.50M0.53M7.80M2.57M12.05M4.03M11.92M2.93M5.66M2.84M23.37M9.74M13.80M
Net Shares Issued and RepurchasedNet Shares Issued
2.17M2.56M0.66M0.68M0.55M2.26M108.84M1.50M0.53M7.80M2.57M12.05M4.03M11.92M2.93M5.66M2.84M23.37M9.74M13.80M
Net Equity Issued and RepurchasedNet Equity Issued
2.17M2.56M0.66M0.68M0.55M2.26M108.84M1.50M7.80M2.57M12.05M4.03M11.92M2.93M5.66M2.84M23.37M9.74M13.80M
Other financing activities (as filed)
-0.19M-0.03M0.00M-0.10M-0.67M-0.60M-0.48M
Cash from Financing ActivitiesCash from Financing
2.17M16.93M0.68M0.68M0.55M26.46M108.17M35.32M0.53M7.20M2.57M12.05M4.03M11.44M2.93M5.66M2.84M23.37M9.74M8.01M
Additional items
Exchange Rate EffectFX Effect
0.02M0.03M-0.02M-0.18M0.08M
Change in Cash
3.12M-25.19M21.76M32.58M-27.07M1.94M107.70M-4.86M-43.80M-14.16M183.08M-224.52M-33.87M42.40M28.96M-54.83M14.68M65.32M226.37M78.22M
Ending Cash Balance
123.89M98.70M120.46M153.04M125.97M127.91M235.61M230.75M186.95M172.79M355.87M131.35M97.47M139.88M168.83M114.00M128.68M194.00M420.37M498.59M
Free Cash FlowFCF
-27.14M-37.94M-13.93M-25.36M-31.71M-34.36M-26.41M-27.02M16.94M-27.67M268.59M-28.64M-29.49M124.82M-29.59M-2.03M-37.12M-49.16M218.88M-23.46M
Net Cash FlowNCF
3.10M-25.22M21.78M32.75M-27.15M1.94M107.70M-4.86M-43.80M-14.16M183.08M-224.52M-33.87M42.40M28.96M-54.83M14.68M65.32M226.37M78.22M

Protagonist Therapeutics Cash Flow Statement API

Pull Protagonist Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PTGX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY